November 10 2011 Idiopathic Pulmonary Fibrosis Drug Market to Grow to $4.6 Billion in 2020

BURLINGTON,
Mass., Nov 10, 2011 (BUSINESS WIRE) — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the idiopathic pulmonary fibrosis (IPF) drug market is forecasted to grow to $4.6 billion in 2020 in the United States and Europe.

Increasing diagnosed and drug-treated populations and the launch of five drugs with novel mechanisms of action are key drivers of this growth. Idiopathic pulmonary fibrosis is one of the most common interstitial lung diseases, and it is the most prevalent pulmonary fibrotic disease.

Read the entire article at:

http://www.marketwatch.com/story/idiopathic-pulmonary-fibrosis-drug-market-to-grow-to-46-billion-in-2020-2011-11-10

or go to www.ipftoday.com for more news.

 

This entry was posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>